Adjuvant immunotherapy (BCG) in Stage D prostate cancer

Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p <0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).